81 results on '"mepolizumab"'
Search Results
2. Real-World Effectiveness of Mepolizumab in Severe Asthma: Results from the Multi-country, Self-controlled Nucala Effectiveness Study (NEST)
3. Effects of Mepolizumab in the treatment of type 2 CRSwNP: a real-life clinical study
4. Reduced Sense of Smell in Patients with Severe Chronic Rhinosinusitis and its Implications for Diagnosis and Management: A Narrative Review
5. Therapie-Update der ANCA-assoziierten Vaskulitiden
6. Healing chronic idiopathic eosinophilic pneumonia using mepolizumab alone without corticosteroids
7. Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP
8. Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy
9. Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study
10. Adverse events of anti-IL-5 drugs in patients with eosinophilic asthma: a meta-analysis of randomized controlled trials and real-world evidence-based assessments
11. When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report
12. Multidisciplinary Decision-Making—ITAlian Consensus After Two Years of Real Practice on the Management of Severe Uncontrolled CRSwNP by Biologics (ITACA Study)
13. Eosinophile Granulomatose mit Polyangiitis (EGPA)
14. Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein–protein interaction analyses
15. Low-dose anti-IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance
16. Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan
17. Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study
18. Can we predict who will benefit most from biologics in severe asthma? A post-hoc analysis of two phase 3 trials
19. Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis
20. The role of anti-eosinophilic therapies in eosinophilic granulomatosis with polyangiitis: a systematic review
21. Treatment with IL5-/IL-5 receptor antagonists in drug reaction with eosinophilia and systemic symptoms (DRESS)
22. Impact of Biologic Therapy on the Small Airways Asthma Phenotype
23. Antikörper bei schwerem Asthma - ein Update
24. Multi-targeted therapy for refractory eosinophilic granulomatosis with polyangiitis characterized by intracerebral hemorrhage and cardiomyopathy: a case-based review
25. Indicating biologics for chronic rhinosinusitis with nasal polyps (CRSwNP): Recommendations by German allergy and ORL societies AeDA and DGHNO for dupilumab, omalizumab, and mepolizumab
26. Aspirin Desensitization in NERD in the Era of Biologics: First or Last Resource?
27. Eosinophile Granulomatose mit Polyangiitis: Update zu Klassifikation und Management
28. Recent Advances in Long-Term Management of Asthma
29. Patient-reported outcome measures after 8 weeks of mepolizumab treatment and long-term outcomes in patients with severe asthma: an observational study
30. The clinical features and treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in Turkey: one or two distinct diseases?
31. Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study
32. Improvement of peripheral neuropathy in a patient with antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis by additional mepolizumab
33. Monoclonal antibodies targeting small airways: a new perspective for biological therapies in severe asthma
34. Refractory flare-up of severe bronchial asthma controlled with mepolizumab due to Pneumocystis pneumonia: a case report
35. Mepolizumab-Induced Posterior Reversible Encephalopathy Syndrome (PRES), a new patient report
36. Biologika beim schweren/schwierigen Asthma bronchiale im Kindes- und Jugendalter
37. Welche Asthmapatienten profitieren von Biologika?
38. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions
39. Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis
40. Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
41. Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials
42. Recurrent atelectasis and brain infarction in a patient with anti-neutrophil antibody negative eosinophilic granulomatosis with polyangiitis: a case report
43. Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series
44. The Current State of Biologic Therapies for Treatment of Refractory Asthma
45. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions
46. Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study
47. Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis
48. Mepolizumab Therapy for Recalcitrant Eosinophilic Annular Erythema in an Adult: A Case Report and Review of Treatment Options
49. Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia
50. Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.